Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Bali, G; Aberer, E.
Iloprost therapy in systemic sclerosis
Hautarzt. 2003; 54(9):845-851
Doi: 10.1007/s00105-003-0578-2
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Aberer Elisabeth
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Systemic sclerosis is an autoimmune disease of unknown origin affecting multiple organ systems. The management of this disease is challenging. Many therapeutic attempts have only been moderately successful. Iloprost, a stable prostacyclin analogue, with its antifibrotic effect can influence an important step in the pathogenesis of systemic sclerosis. In this review we analyze the published data for the optimal dose and duration of treatment. In three different studies, iloprost given for 5 days in the highest tolerated dose of 1-2 ng/kg/min provided a significant improvement of the disease measured by the number and intensity of Raynaud attacks, healing of digital ulcers, and digital perfusion. This improvement lasted for about one month. When the infusions were repeated once a month, treatment effect could be maintained. Although the effect of this treatment regimen should be proven in further long-term studies, we think that an intermittent continuous therapy with iloprost could result in an improvement or stabilization of systemic sclerosis.
- Find related publications in this database (using NLM MeSH Indexing)
- Controlled Clinical Trials -
- Forecasting -
- Humans -
- Iloprost - administration and dosage
- Platelet Aggregation Inhibitors - administration and dosage
- Raynaud Disease - diagnosis
- Scleroderma, Systemic - diagnosis
- Time Factors - diagnosis
- Vasodilator Agents - administration and dosage
- Find related publications in this database (Keywords)
- systemic scleroderma
- iloprost infusion
- Raynaud
- antifibrotic effect